Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)

Drug identity checked against registry records

Also recorded as Darcabazine; Doxorubicin; Gemcitabine + Docetaxel; Ifosfamide; Pazopanib

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 3 Study to Treat Patients With Soft Tissue SarcomasNCT02049905IBRXPhase 3Completed2017-05Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.